USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB
The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Wang, Yong Xing, Yanqiu Zhang, Wenhua Han, Ting Wang, Dan Wang, Shaopeng Li, Xiaonan Xu, Xinglu Jiang, Shengbiao Zhang, Rong Zhu, Hong Xing, Lichao Gao, Yuxia Shao, Shili Liu, Yuanyuan Zheng, Jiahui |
| description | The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024115627A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024115627A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024115627A13</originalsourceid><addsrcrecordid>eNrjZLAODXZV8HdTcPbxDw4J8nTxDPVVcPfw9_P0VAgO8A9yVXD293Xy9HN1UQj3DPFQCHD1dQry9_GMCvV1dOJhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRiaGhqZmRuaOhsbEqQIAkggqYA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB</title><source>esp@cenet</source><creator>Wang, Yong ; Xing, Yanqiu ; Zhang, Wenhua ; Han, Ting ; Wang, Dan ; Wang, Shaopeng ; Li, Xiaonan ; Xu, Xinglu ; Jiang, Shengbiao ; Zhang, Rong ; Zhu, Hong ; Xing, Lichao ; Gao, Yuxia ; Shao, Shili ; Liu, Yuanyuan ; Zheng, Jiahui</creator><creatorcontrib>Wang, Yong ; Xing, Yanqiu ; Zhang, Wenhua ; Han, Ting ; Wang, Dan ; Wang, Shaopeng ; Li, Xiaonan ; Xu, Xinglu ; Jiang, Shengbiao ; Zhang, Rong ; Zhu, Hong ; Xing, Lichao ; Gao, Yuxia ; Shao, Shili ; Liu, Yuanyuan ; Zheng, Jiahui</creatorcontrib><description>The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240411&DB=EPODOC&CC=US&NR=2024115627A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240411&DB=EPODOC&CC=US&NR=2024115627A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Xing, Yanqiu</creatorcontrib><creatorcontrib>Zhang, Wenhua</creatorcontrib><creatorcontrib>Han, Ting</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Wang, Shaopeng</creatorcontrib><creatorcontrib>Li, Xiaonan</creatorcontrib><creatorcontrib>Xu, Xinglu</creatorcontrib><creatorcontrib>Jiang, Shengbiao</creatorcontrib><creatorcontrib>Zhang, Rong</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Xing, Lichao</creatorcontrib><creatorcontrib>Gao, Yuxia</creatorcontrib><creatorcontrib>Shao, Shili</creatorcontrib><creatorcontrib>Liu, Yuanyuan</creatorcontrib><creatorcontrib>Zheng, Jiahui</creatorcontrib><title>USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB</title><description>The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAODXZV8HdTcPbxDw4J8nTxDPVVcPfw9_P0VAgO8A9yVXD293Xy9HN1UQj3DPFQCHD1dQry9_GMCvV1dOJhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRiaGhqZmRuaOhsbEqQIAkggqYA</recordid><startdate>20240411</startdate><enddate>20240411</enddate><creator>Wang, Yong</creator><creator>Xing, Yanqiu</creator><creator>Zhang, Wenhua</creator><creator>Han, Ting</creator><creator>Wang, Dan</creator><creator>Wang, Shaopeng</creator><creator>Li, Xiaonan</creator><creator>Xu, Xinglu</creator><creator>Jiang, Shengbiao</creator><creator>Zhang, Rong</creator><creator>Zhu, Hong</creator><creator>Xing, Lichao</creator><creator>Gao, Yuxia</creator><creator>Shao, Shili</creator><creator>Liu, Yuanyuan</creator><creator>Zheng, Jiahui</creator><scope>EVB</scope></search><sort><creationdate>20240411</creationdate><title>USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB</title><author>Wang, Yong ; Xing, Yanqiu ; Zhang, Wenhua ; Han, Ting ; Wang, Dan ; Wang, Shaopeng ; Li, Xiaonan ; Xu, Xinglu ; Jiang, Shengbiao ; Zhang, Rong ; Zhu, Hong ; Xing, Lichao ; Gao, Yuxia ; Shao, Shili ; Liu, Yuanyuan ; Zheng, Jiahui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024115627A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Xing, Yanqiu</creatorcontrib><creatorcontrib>Zhang, Wenhua</creatorcontrib><creatorcontrib>Han, Ting</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Wang, Shaopeng</creatorcontrib><creatorcontrib>Li, Xiaonan</creatorcontrib><creatorcontrib>Xu, Xinglu</creatorcontrib><creatorcontrib>Jiang, Shengbiao</creatorcontrib><creatorcontrib>Zhang, Rong</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Xing, Lichao</creatorcontrib><creatorcontrib>Gao, Yuxia</creatorcontrib><creatorcontrib>Shao, Shili</creatorcontrib><creatorcontrib>Liu, Yuanyuan</creatorcontrib><creatorcontrib>Zheng, Jiahui</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Wang, Yong</au><au>Xing, Yanqiu</au><au>Zhang, Wenhua</au><au>Han, Ting</au><au>Wang, Dan</au><au>Wang, Shaopeng</au><au>Li, Xiaonan</au><au>Xu, Xinglu</au><au>Jiang, Shengbiao</au><au>Zhang, Rong</au><au>Zhu, Hong</au><au>Xing, Lichao</au><au>Gao, Yuxia</au><au>Shao, Shili</au><au>Liu, Yuanyuan</au><au>Zheng, Jiahui</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB</title><date>2024-04-11</date><risdate>2024</risdate><abstract>The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2024115627A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T09%3A40%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Wang,%20Yong&rft.date=2024-04-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024115627A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |